195 related articles for article (PubMed ID: 28446055)
1. Investigational drugs for nasopharyngeal carcinoma.
Ma BBY; Hui EP; Chan ATC
Expert Opin Investig Drugs; 2017 Jun; 26(6):677-685. PubMed ID: 28446055
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.
Ali SM; Yao M; Yao J; Wang J; Cheng Y; Schrock AB; Chirn GW; Chen H; Mu S; Gay L; Elvin JA; Suh J; Miller VA; Stephens PJ; Ross JS; Wang K
Cancer; 2017 Sep; 123(18):3628-3637. PubMed ID: 28581676
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.
Ma BB; Chan AT
Expert Rev Anticancer Ther; 2006 Mar; 6(3):383-94. PubMed ID: 16503855
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of DNA methylation in Epstein-Barr virus-associated nasopharyngeal carcinoma by bisulfite amplicon sequencing.
Zhao W; Mo Y; Wang S; Midorikawa K; Ma N; Hiraku Y; Oikawa S; Huang G; Zhang Z; Murata M; Takeuchi K
BMC Cancer; 2017 Jul; 17(1):489. PubMed ID: 28716111
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC; Ngan RK; Cheung KM; Cho WC
Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
[No Abstract] [Full Text] [Related]
7. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for nasopharyngeal cancer-a review.
Jain A; Chia WK; Toh HC
Chin Clin Oncol; 2016 Apr; 5(2):22. PubMed ID: 27121882
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges.
Baloche V; Ferrand FR; Makowska A; Even C; Kontny U; Busson P
Expert Opin Ther Targets; 2020 Jun; 24(6):545-558. PubMed ID: 32249657
[No Abstract] [Full Text] [Related]
10. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic landscape of nasopharyngeal carcinoma.
Dai W; Zheng H; Cheung AK; Lung ML
Chin Clin Oncol; 2016 Apr; 5(2):16. PubMed ID: 27121876
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma.
Man CH; Wei-Man Lun S; Wai-Ying Hui J; To KF; Choy KW; Wing-Hung Chan A; Chow C; Tin-Yun Chung G; Tsao SW; Tak-Chun Yip T; Busson P; Lo KW
J Pathol; 2012 Feb; 226(3):471-81. PubMed ID: 22009689
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
Wang S; Chen S; Zhong Q; Liu Y
J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
[TBL] [Abstract][Full Text] [Related]
16. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma.
Chung GT; Lou WP; Chow C; To KF; Choy KW; Leung AW; Tong CY; Yuen JW; Ko CW; Yip TT; Busson P; Lo KW
J Pathol; 2013 Nov; 231(3):311-22. PubMed ID: 23868181
[TBL] [Abstract][Full Text] [Related]
18. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma.
Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H
J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
20. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
